Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Gut hormones in the treatment of short-bowel syndrome and intestinal failure

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Updates in weight loss surgery and gastrointestinal peptides

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic and environmental origins of hypospadias

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Occupational causes of male infertility

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The physiology and timing of male puberty

    Research output: Contribution to journalReviewResearch

  5. Environmental chemicals and thyroid function: an update

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The effect of glucagon-like peptide-1 and glucagon-like peptide-2 on microcirculation: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE OF REVIEW: The approval of teduglutide, a recombinant analog of human glucagon-like peptide (GLP) 2, by the US Food and Drug Administration (Gattex) and the European Medicines Agency (Revestive) has illustrated the potential of selected gut hormones as treatments in patients with short-bowel syndrome and intestinal failure. Gut hormones may improve the structural and functional intestinal adaptation following intestinal resection by decreasing a rapid gastric emptying and hypersecretion, by increasing the intestinal blood flow, and by promoting intestinal growth. This review summarizes the findings from phase 2 and 3 teduglutide studies, and pilot studies employing GLP-1 and agonists for this orphan condition.

RECENT FINDINGS: In a 3-week, phase 2, metabolic balance study, teduglutide increased the intestinal wet weight absorption by approximately 700 g/day and reduced fecal energy losses by approximately 0.8 MJ/day (∼200 Kcal/day). In two subsequent 24-week, phase 3 studies, teduglutide reduced the need for parenteral support in the same magnitude. Adverse events were mainly of gastrointestinal origin and consistent with the known mechanism of action of teduglutide. Pilot studies suggest that GLP-1 may be less potent. Synergistic effects may be seen by co-treatment with GLP-2.

SUMMARY: Gut hormones promote intestinal adaptation and absorption, decreasing fecal losses, thereby decreasing or even eliminating the need for parenteral support. This will aid the intestinal rehabilitation in these severely disabled short-bowel syndrome patients.

Original languageEnglish
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume22
Issue number1
Pages (from-to)14-20
Number of pages7
ISSN1752-296X
DOIs
Publication statusPublished - Feb 2015

    Research areas

  • Clinical Trials, Phase II as Topic, Gastrointestinal Agents, Glucagon-Like Peptide 1, Humans, Intestinal Absorption, Intestine, Small, Parenteral Nutrition, Peptides, Pilot Projects, Quality of Life, Short Bowel Syndrome, United States

ID: 45955529